{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:18:51Z","timestamp":1776788331310,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004409","name":"R\u00e9public Tunisienne Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche Scientifique","doi-asserted-by":"publisher","award":["21PEJC D5P14"],"award-info":[{"award-number":["21PEJC D5P14"]}],"id":[{"id":"10.13039\/501100004409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clim.2026.110679","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:05:22Z","timestamp":1770192322000},"page":"110679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TGF-\u03b21\/TRAF-6 and IL-6\/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer"],"prefix":"10.1016","volume":"284","author":[{"given":"Awatef Ben","family":"Jemaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna Ben","family":"Azaiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sataa","family":"Sallami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Nouira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezzeddine","family":"Ghazouani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridha","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110679_bb0005","first-page":"98","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110679_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.clim.2026.110679_bb0015","doi-asserted-by":"crossref","first-page":"T95","DOI":"10.1530\/ERC-21-0149","article-title":"The tumor microenvironment and immune responses in prostate cancer patients","volume":"28","author":"Kwon","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.clim.2026.110679_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cdp.2008.02.007","article-title":"Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer","volume":"32","author":"Bouraoui","year":"2008","journal-title":"Cancer Detect. Prev."},{"issue":"6","key":"10.1016\/j.clim.2026.110679_bb0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/biom15060826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.clim.2026.110679_bb0030","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"issue":"12","key":"10.1016\/j.clim.2026.110679_bb0035","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.3390\/biomedicines11123140","article-title":"Inflammation in prostate cancer: exploring the promising role of phenolic compounds as an innovative therapeutic approach","volume":"11","author":"Fernandes","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clim.2026.110679_bb0040","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1158\/0008-5472.CAN-08-1125","article-title":"Activation of Stat3 through a phosphomimetic Serine727 promotes prostate tumorigenesis independent of Tyrosine705 phosphorylation","volume":"68","author":"Qin","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.clim.2026.110679_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/imr.12302","article-title":"Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system","volume":"266","author":"Walsh","year":"2015","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.clim.2026.110679_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.kjms.2017.10.002","article-title":"Immune profiling of human prostate epithelial cells determined by expression of p38\/TRAF-6\/ERK MAP kinases pathways","volume":"34","author":"Bouraoui","year":"2018","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.clim.2026.110679_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.688489","article-title":"A double-edged sword role of cytokines in prostate Cancer immunotherapy","volume":"11","author":"Mao","year":"2021","journal-title":"Front. Oncol."},{"issue":"49","key":"10.1016\/j.clim.2026.110679_bb0060","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.clim.2026.110679_bb0065","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1210\/mend-5-12-1921","article-title":"The promoter of the prostate-specific antigen gene contains a functional androgen responsive element","volume":"5","author":"Riegman","year":"1991","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.clim.2026.110679_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/geno.2000.6446","article-title":"A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1","volume":"73","author":"Watt","year":"2001","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.clim.2026.110679_bb0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/pros.20531","article-title":"Does PSA play a role as a promoting agent during the initiation and\/or progression of prostate cancer?","volume":"67","author":"Williams","year":"2007","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.clim.2026.110679_bb0080","first-page":"C975","article-title":"Is prostate-specific membrane antigen a multifunctional protein?","volume":"288","author":"Rajasekaran","year":"2005","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.clim.2026.110679_bb0085","first-page":"2702","article-title":"Serum interleukin 6 as a prognostic factor in patients with prostate cancer","volume":"6","author":"Nakashima","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110679_bb0090","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"Michalaki","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.clim.2026.110679_bb0095","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.imbio.2016.07.002","article-title":"Cytokine profiling identifies an interaction of IL-6 and IL-1\u03b1 to drive PSMA-PSA prostate clones","volume":"221","author":"Jemaa","year":"2016","journal-title":"Immunobiology"},{"issue":"8","key":"10.1016\/j.clim.2026.110679_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03723-4","article-title":"Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110679_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585880","article-title":"Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects","volume":"11","author":"Gough","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110679_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/f290f38a-4f71-43ad-b988-9f8d5a7329fe","article-title":"The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways","volume":"4","author":"Colombatti","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.clim.2026.110679_bb0115","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-03-3486","article-title":"Androgen receptor signaling: mechanism of interleukin-6 inhibition","volume":"64","author":"Jia","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2026.110679_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1479505","article-title":"The role of interleukin-17 in inflammation-related cancers","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2026.110679_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","article-title":"Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate","volume":"56","author":"Steiner","year":"2003","journal-title":"Prostate"},{"issue":"5A","key":"10.1016\/j.clim.2026.110679_bb0130","first-page":"3409","article-title":"IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis","volume":"26","author":"Cardillo","year":"2006","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.clim.2026.110679_bb0135","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/pros.23842","article-title":"Circulating inflammation markers and prostate cancer","volume":"79","author":"Ugge","year":"2019","journal-title":"Prostate"},{"issue":"28","key":"10.1016\/j.clim.2026.110679_bb0140","doi-asserted-by":"crossref","first-page":"45994","DOI":"10.18632\/oncotarget.17522","article-title":"The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies","volume":"8","author":"Men","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2026.110679_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5305306","article-title":"Interleukin-10 induces expression of neuroendocrine markers and PDL1 in prostate Cancer cells","volume":"2020","author":"Samiea","year":"2020","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.clim.2026.110679_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cyto.2016.08.008","article-title":"Expression of several cytokines in prostate cancer: correlation with clinical variables of patients. Relationship with biochemical progression of the malignance","volume":"89","author":"Torrealba","year":"2017","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.clim.2026.110679_bb0155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.31557\/APJCP.2024.25.2.709","article-title":"Clinical assessment of TGFB1 and HP relative gene expression in the peripheral blood of prostate cancer patients","volume":"25","author":"Yahya","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.clim.2026.110679_bb0160","first-page":"318","article-title":"Alterations in TGF\u03b2 signaling during prostate cancer progression","volume":"9","author":"Thompson-Elliott","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"5","key":"10.1016\/j.clim.2026.110679_bb0165","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2007.03.014","article-title":"T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation","volume":"26","author":"Li","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110679_bb0170","article-title":"AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancer","author":"Massah","year":"2025","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.clim.2026.110679_bb0175","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cbin.10055","article-title":"A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells","volume":"37","author":"Ben Jemaa","year":"2013","journal-title":"Cell Biol. Int."},{"issue":"4","key":"10.1016\/j.clim.2026.110679_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/pros.10199","article-title":"Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models","volume":"54","author":"Denmeade","year":"2003","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.clim.2026.110679_bb0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2164\/jandrol.106.000141","article-title":"Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy","volume":"27","author":"Maggio","year":"2006","journal-title":"J. Androl."},{"key":"10.1016\/j.clim.2026.110679_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114168","article-title":"STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions","volume":"158","author":"Sadrkhanloo","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.clim.2026.110679_bb0195","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1101\/gad.1553707","article-title":"Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB","volume":"21","author":"Yang","year":"2007","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.clim.2026.110679_bb0200","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/pros.22805","article-title":"Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment","volume":"74","author":"Zhang","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.clim.2026.110679_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/14796694.5.1.1","article-title":"TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells","volume":"5","author":"Thakur","year":"2009","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.clim.2026.110679_bb0210","first-page":"563","article-title":"Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases","volume":"2","author":"O\u2019Brien","year":"2008","journal-title":"Biologics"},{"issue":"9","key":"10.1016\/j.clim.2026.110679_bb0215","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/cancers12092382","article-title":"Angiogenesis inhibition in prostate cancer: an update","volume":"12","author":"Sarkar","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clim.2026.110679_bb0220","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR Tcells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:28:31Z","timestamp":1776785311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["S1521661626000173"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110679","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TGF-\u03b21\/TRAF-6 and IL-6\/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110679"}}